Compass Therapeutics’ (CMPX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report published on Monday,Benzinga reports. The brokerage currently has a $32.00 target price on the stock.

A number of other research analysts also recently issued reports on CMPX. HC Wainwright raised their price target on shares of Compass Therapeutics from $10.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, April 4th. Jefferies Financial Group lifted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, Guggenheim reaffirmed a “buy” rating and issued a $12.00 target price on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $13.38.

Compass Therapeutics Stock Performance

CMPX opened at $1.78 on Monday. The company has a market capitalization of $246.14 million, a P/E ratio of -4.81 and a beta of 1.40. The company has a 50-day moving average of $2.33 and a 200-day moving average of $2.09. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, sell-side analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Anderman bought 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The shares were acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at $32,340. This represents a 2,000.00 % increase in their position. The disclosure for this purchase can be found here. 28.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Compass Therapeutics

Several large investors have recently modified their holdings of CMPX. Tower Research Capital LLC TRC lifted its holdings in shares of Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new stake in Compass Therapeutics during the 4th quarter worth about $26,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics during the fourth quarter valued at about $27,000. Mariner LLC acquired a new position in shares of Compass Therapeutics in the fourth quarter worth about $30,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Compass Therapeutics in the fourth quarter worth approximately $35,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.